Synonym
Acetrizoic Acid; Opacaron; Urokon;
IUPAC/Chemical Name
3-Acetamido-2,4,6-triiodobenzoic acid
InChi Key
GNOGSFBXBWBTIG-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H6I3NO3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)
SMILES Code
O=C(O)C1=C(I)C=C(I)C(NC(C)=O)=C1I
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
556.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: The MICAD Research Team. N-(2,3-Dihydroxypropyl)-N´-(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl)acetamido]- 2,4,6-triiodoisophthalamide. 2006 Jul 12 [updated 2006 Aug 9]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK26369/ PubMed PMID: 20641973.
2: Cheng KT. N,N´-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl-3-methoxypropyl)-acetamidol]-2 ,4,6-triiodoisophthalamide. 2006 Mar 6 [updated 2008 Mar 4]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK26367/ PubMed PMID: 20641971.
3: Cheng KT. N,N´-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)-glycolamidol]-2,4,6-triiodois ophthalamide. 2006 Feb 7 [updated 2008 Feb 7]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK26366/ PubMed PMID: 20641970.
4: Cheng KT. 5-[3-Hydroxy-2-hydroxymethyl-propionamido)-N,N´-dimethyl-N,N´-bis-(2,3-dihydroxyp ropyl)-2,4,6-triiodoisophthalamide. 2006 May 16 [updated 2008 Apr 21]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK25584/ PubMed PMID: 20641966.
5: Sergeev PV, Sviridov NK. [Effect of contrast media on the cardiovascular system (review of the literature)]. Farmakol Toksikol. 1977 Jul-Aug;40(4):498-503. Review. Russian. PubMed PMID: 332518.
6: Classen JN, Martin RE, Thompson NO. Complications of colon and rectum following diagnosis. Prophylaxis and therapy. Acta Chir Belg. 1977 May-Jun;76(3):235-47. Review. PubMed PMID: 331814.
7: Lazecki L. [Nephrotropic contrast media]. Pol Przegl Radiol Med Nukl. 1975 Mar-Apr;39(2):239-50. Review. Polish. PubMed PMID: 1096096.
8: Saxton HM. Review article: urography. Br J Radiol. 1969 May;42(497):321-46. Review. PubMed PMID: 4914357.
